On March 1, 2022 Hera BioLabs, an innovative service and technology provider with novel genetic engineering products, reported a collaboration with Charles River Laboratories, International Inc. for a global license agreement to commercialize Hera’s SRGTM rat (OncoRat) (Press release, Hera BioLabs, MAR 1, 2022, View Source [SID1234610113]). The SRG rat is the first highly immunocompromised rat model, validated for xenograft studies in oncology and infectious disease research applications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under this new collaborative agreement, Charles River will breed, distribute, sell, and market the SRG rat directly to the preclinical research community, while Hera will focus on providing services utilizing the model.

Hera BioLabs CEO, Dr. Mike Schlosser, commented, "We are very pleased to be working with Charles River, a company known for delivering high quality products and services for drug discovery and development. Their confidence in Hera’s SRG rat as an emerging go-to model is evidenced by this collaboration and highlights the transformative technology offered by Hera. This agreement creates substantial opportunities for Hera BioLabs to grow our SRG rat franchise in conjunction with Charles River’s portfolio expansion, bringing high quality research models to investigators world-wide."

Colin Dunn, Corporate Senior Vice President of Charles River’s Research Model and Services, commented, "We are thrilled to add the SRG rat to our portfolio of research models, which will expand the availability and distribution of this impactful oncology model for preclinical research."

Jazz Pharmaceuticals has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Epizyme has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 1, 2022 Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology, reported the hiring of Dr. Margaret Wasilewski as the Company’s Chief Medical Officer effective March 1st, 2022 (Press release, Pulmatrix, MAR 1, 2022, View Source [SID1234609515]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud to welcome Dr. Wasilewski to the Pulmatrix Executive Team," said Ted Raad, Chief Executive Officer of Pulmatrix. "She brings extensive experience across different stages of pharmaceutical drug development in various therapeutic areas. Pulmatrix will immediately benefit from her leadership in the clinical strategy and delivery of the clinical trial milestones. She will also be my partner in charting the direction of our current and future pipeline. I am excited about the deep capabilities that Dr. Wasilewski will add to the Pulmatrix team as we look to further develop our pipeline."

Dr. Wasilewski leverages over 25 years of experience in pharmaceutical drug development. She led the clinical development program for treatment and recurrence prevention in Clostridioides difficile infection as Vice President Research and Development-Medical at Summit Therapeutics. Dr. Wasilewski held various leadership roles at Eli Lilly and Company, Targanta Therapeutics, and Shire. Her clinical development experience includes bacterial and viral infections, sepsis, neurology, and rare disease. As President of ID Remedies, LLC, she has provided scientific, medical, and regulatory consultation and business development to various biopharmaceutical companies.

Dr. Wasilewski received a medical degree from Tufts University School of Medicine and is board certified in Internal Medicine and completed fellowships in Infectious Diseases and Clinical Pharmacology at the University of California-San Francisco. Dr. Wasilewski received an MBA from Indiana University, Kelly School of Business; a master’s degree in Nutrition from the University of California-Berkeley and an undergraduate degree in Chemistry from Rutgers University.

Dr. Wasilewski added, "I am thrilled to join Pulmatrix at such an exciting time. The current pipeline has potential to address important unmet needs in both respiratory and neurological disease, while the iSPERSE technology provides opportunity to expand into new areas of unmet need. I look forward applying my experience to position Pulmatrix for long-term success."

On March 1, 2022 Sterling Pharma Solutions, a global contract development and manufacturing organisation, reported that it had reached agreement with Novartis to acquire its Ringaskiddy campus (Novartis Ringaskiddy Limited), near Cork, Ireland. Financial details of the sale, which is expected to close in Q4, 2022, have not been disclosed (Press release, Novartis, MAR 1, 2022, View Source [SID1234609418]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Sterling will acquire the 111-acre site, which includes three active pharmaceutical ingredient (API) manufacturing buildings, as well as facilities to support development and scale up in line with Sterling’s core business focus. The site currently manufactures a number of APIs across a range of therapeutic areas, and the deal includes an ongoing supply agreement between Sterling and Novartis from the Ringaskiddy facility. Upon closing, the workforce will transition to Sterling.

Sterling’s Chief Executive Officer, Kevin Cook, said: "The addition of this new, world-class facility and its highly skilled workforce, with its history of quality and regulatory excellence, to Sterling’s portfolio, will enable us to provide expanded capacity to our customers. The site at Ringaskiddy has a number of synergies with our current global facilities enabling us to continue our growth strategy in the small molecule market, as well as extending our capabilities in several key technological areas such as peptide manufacturing and large-scale chromatography."

This announcement follows several investments in Sterling’s manufacturing capabilities in 2021, as well as the acquisition of its Germantown site in Wisconsin from Alcami in 2020, and a dedicated antibody-drug conjugate facility in Deeside, UK in 2021.

The addition of the Ringaskiddy campus will see Sterling’s global network grow to five facilities across the UK, Europe and the US, with a workforce of over 1,000 employees.